|Description||Fosdevirine is a highly potent next-generation Anti-HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 11 nM. It is a novel and once-daily (QD) inhibitor with activity against efavirenz-resistant strains. It demonstrated potent antiviral activity in treatment-naive HIV-infected subjects, and had favorable PK and resistance profiles. It was originally developed by idenix pharmaceuticals and was in clinical phase 2, but now it has been terminated.|
|Solubility||10 mM in DMSO|
|Application||Fosdevirine has potent antiviral activity.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||686.4±65.0 °C | Condition: Press: 760 Torr|
|Density||1.42±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Fosdevirine was originally developed by idenix pharmaceuticals and was in clinical phase 2, but now it has been terminated.|
Fosdevirine is a highly potent next-generation Anti-HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 11 nM. It is a novel and once-dail...
The labeled form of Etravirine, is an inhibitor of HIV reverse transcriptase, could be used in the treatment of HIV infection.
CP-94707 is a new nonnucleoside reverse transcriptase inhibitor (NNRTI).
IDX899 is a novel next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with activity against efavirenz-resistant strains. It is used in the tre...
Rilpivirine, also known as TMC278, is a drug used as part of antiretroviral therapy (ART). Rilpivirine is a second-generation non-nucleoside reverse transcripta...